drugset / Trial / NCT01459926

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation

NCT01459926

Phase 2 Completed 217 enrolled Glycyx Therapeutics Theravance Biopharma · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects with Opioid-Induced Constipation

Timeline

Start
2011-11
Primary completion
2012-05
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject axelopran Small molecule